Transcode Therapeutics Inc
transcodetherapeutics.comWhat Do They Do?
Develops RNA-based cancer drug candidates and immunotherapies for people with advanced cancers.
10-K for FY2025, filed Apr 15, 2026TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers. Our…View ↗
ABCJ owns 100% of the issued and outstanding membership interests of Polynoma, LLC, a Delaware limited liability company, (“Polynoma”)…View ↗
Under the Unleash Licensing Agreement, we acquired rights to three compounds, UIO 524, UIO 525 and UIO 526, that we believe complement and…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Apr 15, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$6.8MView ↗
- ▲ +58% (Loss)
- vs −$4.3M in Q2 FY2025
-
Sep 9, 2026
Chief financial officer resigns; interim CFO appointed
Thomas A. Fitzgerald resigned as CFO and director, and John Tattory was appointed interim CFO.
Sources
8-K, filed Sep 11, 2026
On September 10, 2026, TransCode Therapeutics, Inc. (the “Company”) announced that Thomas A. Fitzgerald, M.B.A. had resigned as Chief…View ↗
Broader cancer-treatment pipeline
The older report centered on RNA therapeutics and included gene-editing and mRNA-vaccine platforms; the latest report adds a melanoma vaccine program and an oncolytic immunotherapy platform.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Apr 15, 2026
Who Do They Compete With?
Competes with Arrowhead Pharmaceuticals, Ionis, Moderna, Alnylam, BioNTech, Dicerna, and Siranomics
10-K for FY2025, filed Apr 15, 2026There are a number of oncology companies with targeted therapeutics for various cancers with therapeutic candidates in various stages of…View ↗
Loading...
